@PersimmonTI $ONC told us it's paused the trial while it evaluates data. No idea what's prompted that, but a tox signal seems possible.
...and now $ONC EGFR degrader BG-60366 appears to have been discontinued - recruitment ended after enrolling just 33 of planned 93 patients.
@STL_Biotech $ONC for instance: https://t.co/LFJCsl1MQj
Since my 2024 look at CCR8 a lot has happened: $BMY $GILD $ABBV upsized; $ONC Bayer $ZLAB (& soon $AMGN?) discontinued. @BatirtzeAreitio investigates, via @ApexOnco -> https://t.co/hUweyScpAN $CHRS $RHHBY
If $ABBV BTK degrader ABBV-101 has been discontinued (Evercore ISI confirms to us that it has) that's good news for $ONC & $NRIX -> https://t.co/aF1sORkqDY
Ascentage just disclosed that it's developing a BTK degrader: APG-3288 apparently just had its US IND cleared $ONC $NRIX
That's confirmed now - #GI26 late-breaking abstract LBA285 $JAZZ $ONC $ZYME
$AZN follows $LLY $PFE $AMGN $ONC & $ALPMF into pan-KRAS, but should it be looking more to pan-RAS approaches like $RVMD & $ERAS? Via @ApexOnco -> https://t.co/MioOWziuSt
@NotGenentech @bioinvestor24 Here's a list of just the clinical pan-RAS & pan-KRAS assets from Oncologypipeline $RVMD $LLY $ONC $RHHBY $PFE $ERAS $AZN $AMGN $ALPMF https://t.co/oeb4Yr2nzo
If you enjoyed #ASH25 you can catch up on all @ApexOnco coverage, including previews, here -> https://t.co/XIQrEeKMwY $TERN $JNJ $LLY $CGEM $ONC $NRIX $PFE $REGN $KURA
$LLY Jaypirca looks best... up to a point. Via @ApexOnco from #ASH25 https://t.co/SgHJrraNrI $ONC $AZN $JNJ $ABBV $NRIX
$NRIX +23% surprises me. I thought the #ASH25 data showed $ONC to be better on efficacy (with caveats), albeit worse on safety. My earlier take on @ApexOnco -> https://t.co/rPlUpNBAlV
By my calculation $ONC now has an efficacy edge vs $NRIX in BTK degradation. Caveats: small pt numbers, X-trial comparison, and Nurix might have the safety advantage #ASH25 https://t.co/MRzhth50rC
If you need some biotech reading over Thanksgiving check out @ApexOnco previews of #ASH25 --> https://t.co/cqsR1AVbPH Starts in just over a week! $ACLX $ONC $CRVS $TERN $KURA $SNDX $CGEM $INCY
Just accepted for FDA priorty review. "The treatment was well tolerated, and the risks were manageable", so that's all right then! $ONC
First $AFMD, now $IPHA... what say $ONC & any others still involved in NK-cell engagers?
Nanjing Leads IPO document reveals that $ONC terminated its Lag3 deal in May. Should start trading tomorrow. Via @ApexOnco -> https://t.co/njxW3Ih5vU
Guess who's about to take a SC anti-PD-1 into phase 3? Via @ApexOnco -> https://t.co/TNXStCSSIo $ONC $BGNE $RHHBY $AZN $MRK $BMY $PFE
$ONC $BGNE confirmed to us that it's working both on a Ras(on) inhibitor, and on developing ADCs that use this Ras(on) inhibitor as a "non-cytotoxic payload".
You already have a small-molecule inhibitor, so do you also need a degrader? $ONC $BGNE thinks yes, for BTK, CDK2 & Kras. Via @ApexOnco -> https://t.co/LFJCsl1MQj $ARVN $GILD $RVMD
